ArticleJAMA network open2021
Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma.
Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Molecular profiling and personalized medicine within EURACAN in the SPECTA Arcagen study in comparison to the France Genomic Medicine 2025 Plan in the AURAGEN platform in peritoneal mesotheliomas.Translational oncology · 2026Article
- Consensus Guideline for the Management of Peritoneal Mesothelioma.Annals of surgical oncology · 2026Review
- Case Report: Iparomlimab and Tuvonralimab-based therapy for epithelioid malignant peritoneal mesothelioma: a three-case series.Frontiers in oncology · 2026Article
- Elevated Proportion of Tumor-Infiltrating Natural Killer Cells Predicts Improved Survival in Peritoneal Mesothelioma: A Single-Center Study of 109 Cases.Annals of surgical oncology · 2026Article
- Assessing the Annual Risk of Recurrence Following Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Diffuse Malignant Peritoneal Mesothelioma Patients.Annals of surgical oncology · 2025Article
- Unraveling Peritoneal Mesothelioma: A Case-Based Discussion on Diagnosis and Management.Cureus · 2025Article
- Navigating Fertility Preservation in Epithelioid Peritoneal Mesothelioma: A Case Study.The American journal of case reports · 2025Article
- Pembrolizumab as an effective treatment for diffuse malignant peritoneal mesothelioma with long‑term survival: A case report and literature review.Oncology letters · 2025Article
- Surgical and oncological outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma : A retrospective single center experience.Wiener klinische Wochenschrift · 2025Article
- Malignant mesothelioma in rare sites: two case reports.Frontiers in oncology · 2025Article
- Biomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review).Oncology letters · 2024Review
- The rare occurrence of unifocal peritoneal mesothelioma: a case report, literature review, and future directions.Journal of gastrointestinal oncology · 2024Article
- Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature.Frontiers in oncology · 2024Article
- A Complete Response to Pembrolizumab in Malignant Peritoneal Mesothelioma: A Case Report.Cureus · 2024Article
- Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma.Cancers · 2023Review
- Immunotherapy in malignant peritoneal mesothelioma (Review).Molecular and clinical oncology · 2023Review
- Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma.JAMA network open · 2023Article
- Review
- Advances in the management of peritoneal malignancies.Nature reviews. Clinical oncology · 2022Review
- Malignant peritoneal mesothelioma literature review: past, present, and future.Digestive medicine research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.